Pacira Biosciences, Inc. (PCRX) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

IDEAYA Biosciences, Inc.

Vericel Corp.

Springworks Therapeutics, Inc.

Taro Pharmaceutical Industries Ltd.

Ironwood Pharmaceuticals, Inc.

CureVac NV

Pacira Biosciences, Inc.

PTC Therapeutics, Inc.

Crinetics Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc.

Biohaven Ltd.

Why is Pacira Biosciences, Inc. ?

Negative results in Jun 25

OPERATING CASH FLOW(Y) Lowest at USD 134.52 MM
INTEREST(HY) At USD 9.28 MM has Grown at 28.82%
ROCE(HY) Lowest at -15.57%

With ROCE of 10.10%, it has a risky valuation with a 1.45 Enterprise value to Capital Employed

The stock is trading at a discount compared to its peers' average historical valuations
Over the past year, while the stock has generated a return of 33.01%, its profits have fallen by -2.3%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Pacira Biosciences, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Pacira Biosciences, Inc.

43.76%

-0.44

44.82%

S&P 500

13.22%

0.61

20.17%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

11.57%

EBIT Growth (5y)

14.46%

EBIT to Interest (avg)

3.79

Debt to EBITDA (avg)

1.43

Net Debt to Equity (avg)

0.12

Sales to Capital Employed (avg)

0.50

Tax Ratio

52.45%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

9.06%

ROE (avg)

10.91%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.51

EV to EBIT

14.36

EV to EBITDA

7.56

EV to Capital Employed

1.45

EV to Sales

1.85

PEG Ratio

Dividend Yield

ROCE (Latest)

10.10%

ROE (Latest)

7.73%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Bullish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bullish

Dow Theory

No Trend

OBV

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

1What is working for the Company

RAW MATERIAL COST(Y)

Fallen by -3.69% (YoY

-26What is not working for the Company

OPERATING CASH FLOW(Y)

Lowest at USD 134.52 MM

INTEREST(HY)

At USD 9.28 MM has Grown at 28.82%

ROCE(HY)

Lowest at -15.57%

INVENTORY TURNOVER RATIO(HY)

Lowest at 1.68 times

PRE-TAX PROFIT(Q)

Lowest at USD -1.29 MM

NET PROFIT(Q)

Lowest at USD -4.21 MM

Here's what is working for Pacira Biosciences, Inc.

Raw Material Cost

Fallen by -3.69% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Depreciation

Highest at USD 27.32 MM

in the last five periods

MOJO Watch

The expenditure on assets done by the company may have gone into operation

Depreciation (USD MM)

Depreciation

At USD 27.32 MM has Grown at 29.07%

period on period (QoQ)

MOJO Watch

The expenditure on assets done by the company has gone into productive use which should positively reflect in the future sales

Depreciation (USD MM)

Here's what is not working for Pacira Biosciences, Inc.

Pre-Tax Profit

At USD -1.29 MM has Fallen at -104.07%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit

At USD -4.21 MM has Fallen at -125.66%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Interest

At USD 9.28 MM has Grown at 28.82%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Operating Cash Flow

Lowest at USD 134.52 MM

in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Pre-Tax Profit

Lowest at USD -1.29 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Net Profit

Lowest at USD -4.21 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is negative

Net Profit (USD MM)

Inventory Turnover Ratio

Lowest at 1.68 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio